ID   UCRU-BL-17
AC   CVCL_M007
SY   UCRU-BL-17-CL; UCRU-BL-17CL; UCRU BL 17CL; UCRU-BL 17; BL-17; BL17
DR   Cosmic; 735768
DR   Cosmic; 928828
DR   Cosmic; 1927311
DR   Wikidata; Q54989701
RX   Patent=US5622836;
RX   PubMed=2328200;
RX   PubMed=2418959;
RX   PubMed=2685375;
RX   PubMed=3335421;
RX   PubMed=8635192;
RX   PubMed=8873383;
RX   PubMed=9246190;
RX   PubMed=23401075;
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 07-09-18; Version: 8
//
RX   Patent=US5622836;
RA   Walker K.Z., Russell P.J.;
RT   "Monoclonal antibodies which recognize malignant cells from bladder
RT   carcinomas.";
RL   Patent number US5622836, 22-Apr-1997.
//
RX   PubMed=2328200; DOI=10.1038/bjc.1990.81;
RA   Brown J.L., Russell P.J., Philips J., Wotherspoon J., Raghavan D.;
RT   "Clonal analysis of a bladder cancer cell line: an experimental model
RT   of tumour heterogeneity.";
RL   Br. J. Cancer 61:369-376(1990).
//
RX   PubMed=2418959;
RA   Russell P.J., Raghavan D., Gregory P., Philips J., Wills E.J.,
RA   Jelbart M., Wass J., Zbroja R.A., Vincent P.C.;
RT   "Bladder cancer xenografts: a model of tumor cell heterogeneity.";
RL   Cancer Res. 46:2035-2040(1986).
//
RX   PubMed=2685375; DOI=10.1016/S0022-5347(17)39172-3;
RA   Walker K.Z., Russell P.J., Kingsley E.A., Philips J., Raghavan D.;
RT   "Detection of malignant cells in voided urine from patients with
RT   bladder cancer, a novel monoclonal assay.";
RL   J. Urol. 142:1578-1583(1989).
//
RX   PubMed=3335421; DOI=10.1002/ijc.2910410115;
RA   Russell P.J., Jelbart M., Wills E., Singh S., Wass J., Wotherspoon J.,
RA   Raghavan D.;
RT   "Establishment and characterization of a new human bladder cancer cell
RT   line showing features of squamous and glandular differentiation.";
RL   Int. J. Cancer 41:74-82(1988).
//
RX   PubMed=8635192; DOI=10.1007/BF01526554;
RA   Kingsley E.A., Carter T.E., Barrow K.D., Russell P.J.;
RT   "Characterisation of the anti-bladder-cancer monoclonal antibody
RT   BLCA-8: identification of its antigen as a neutral glycolipid.";
RL   Cancer Immunol. Immunother. 41:348-354(1995).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=9246190; DOI=10.1080/09553009714349;
RA   Ribeiro J.C.C., Barnetson A.R., Fisher R.J., Mameghan H., Russell P.J.;
RT   "Relationship between radiation response and p53 status in human
RT   bladder cancer cells.";
RL   Int. J. Radiat. Biol. 72:11-20(1997).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y., Chekaluk Y., Zhang J., Du J., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//